GLP-1 drugs may prevent deadly heart complications after heart attack
Researchers from the University of Bristol and University College London (UCL) discovered that GLP-1 receptor agonists (the class including semaglutide in Ozempic/Wegovy and tirzepatide in Mounjaro) can prevent a deadly post-heart attack complication called “no-reflow” — which strikes up to 50% of patients even after doctors successfully reopen the main blocked artery. sciencedirect.com frontiersin.org What … Read more
